<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198402</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190427</org_study_id>
    <nct_id>NCT04198402</nct_id>
  </id_info>
  <brief_title>Microbiotic Analysis in Digestive Endocrine Tumors</brief_title>
  <acronym>MicroTEND</acronym>
  <official_title>Microbiotic Analysis in Digestive Endocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual
      microbiota is a way to explore new neoplastic mechanisms, tumor identification and
      therapeutic orientations. This prospective pilot study aims to describe fecal bacterial
      phylogeny of patients with digestive neuroendocrine tumor.

      Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive
      patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or
      locally advanced, as well as after one year follow up.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bacterial genomic signature</measure>
    <time_frame>Baseline visit</time_frame>
    <description>bacterial genomic signature by fecal ARN16S analysis at enrollment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Digestive Neuroendocrine Tumor</condition>
  <condition>Fecal Microbiota</condition>
  <condition>Bacterial Signature</condition>
  <arm_group>
    <arm_group_label>Patient with digestive neuroendocrine tumor</arm_group_label>
    <description>naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without tumor</arm_group_label>
    <description>Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological sampling</intervention_name>
    <description>Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing</description>
    <arm_group_label>Patient with digestive neuroendocrine tumor</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fecal sample blood sample

      blood sample is part of routine medical care and fecal sample is a non invasive collection of
      elements from human body, allowing the study to be categorised as a non-interventional
      research (approved by ethics commitee)

      Please see:

      &quot;Arrêté du 12 avril 2018 fixant la liste des recherches mentionnées au 3° de l'article L.
      1121-1 du code de la santé publique&quot; , justifying observational study type
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per
        endoscopy or on surgical specimen) or small intestine), secreting or not, going to receive
        Lanreotide treatment as the first line therapy for their disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or older

          -  naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per
             endoscopy or on surgical specimen) or small intestine), secreting or not, initiating a
             extended release Lanreotide treatment

          -  registered with a social security scheme

        Exclusion Criteria:

          -  medical contraindication to somatostatine analogs use

          -  history of extended release somatostatine analogs treatment

          -  antibiotic use or colonoscopic purge in the last 3 weeks preceding fecal sample

          -  pregnant or breastfeeding women

          -  person requiring tutorship, guardianship, or person legally protected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>IRADJ SOBHANI, MD-PHD</last_name>
    <phone>01 49 81 23 62</phone>
    <phone_ext>0033</phone_ext>
    <email>iradj.sobhani@aphp.fr</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data are own by Assistance Publique - Hopitaux de Paris, please contact sponsor for further information</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

